

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
SCRIPPS RESEARCH INSTITUTE	05/17/2002
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6376170
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director,DEITR, NIH
Total Attachments: 1 source=6376170mrs-p0001 - p0002#page2.tif	

7375802-93-098

LICENSE TO THE UNITED STATES GOVERNMENT

This instrument confers to the United States Government, as represented by the Department of Health and Human Services, a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject invention:

TSRI No.: 414.0 C1/ Discl. 93-071
Invention Title: "Ligand Capture-Directed Selection of Antibody"
Inventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson
and Pietro P. Sanna
U.S. Patent No.: 6,376,170 B1
Issued Date: Apr. 23, 2002
Title: "Ligand Capture-Directed Selection of Antibody"
Country, if other than United States:

This subject invention was conceived or first actually reduced to practice in performance of a government-funded project, National Institutes of Health Grant Nos. AI 33292 & AI 35165.

Principal rights to this subject invention have been left with the Licensor: **THE SCRIPPS RESEARCH INSTITUTE**, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed: _____

Arnold LaGuardia
Executive Vice President
The Scripps Research Institute

Date: _____

5/17/02